Daily Market Briefing

2026-09-28 · Money Checkup market briefing

# Mixed Signals as Biotech Surges, Commodities Tumble

The broader market finished in the red on September 28th, with all major indices closing down roughly 0.7–0.9%, but the real story wasn't the modest retreat—it was the violent divergence underneath. While the S&P 500 slipped to 7683.69 and the Nasdaq fell 0.92%, a handful of names posted truly eye-popping moves that underscore just how fragmented this market has become.

Kodiak Sciences (KOD) led the charge with a stunning 178% gain, making it by far the day's most dramatic move. That kind of spike typically signals either major clinical news, regulatory approval, or a significant corporate event—though without additional context from the data provided, the specific catalyst remains unclear. Beyond Kodiak, biotech and healthcare stocks dominated the gainers' list: Nautilus Biotechnology (NAUT) +15.3%, Annexon (ANNX) +10.2%, and AbCellera Biologics (ABCL) +9.6% all moved sharply higher. In fact, the broader Biotechnology Laboratory Analytical Instruments industry group posted a +10.9% gain across 11 companies, suggesting sector-wide momentum. That wasn't limited to pure biotech; Consumer Specialties rose 14.5%, led by names like Signet Jewelers and Fossil Group. Even AMC Entertainment Holdings (AMC) managed a surprising +11.9%, adding to the eclectic mix of winners.

The losers, by contrast, painted a picture of rotation away from commodity exposure and select growth names. Getty Images Holdings (GETY) plummeted 40.8%—a graphic reminder that even established brands can face structural headwinds. More broadly, coal, metals, and aluminum all suffered steep declines: Coal Mining fell 20.2%, Metal Mining dropped 16.3%, and Aluminum slumped 18.0%. Tobacco stocks also got hammered, with that industry down 28.3 percent. MongoDB (MDB), a key player in cloud infrastructure, shed 18.5%, while several smaller-cap biotech names like Chemomab (CMMB) and Jaguar Health (JAGX) fell sharply despite the sector's overall strength—a reminder that not all biotech is created equal. Notably, five companies currently carry going-concern audit flags (Entrada Therapeutics, FS KKR Capital, New Mountain Finance, Bain Capital Specialty Finance, and Innovative Industrial Properties), signaling potential financial distress for investors in those names.

Several companies also crossed the finish line with fresh annual filings. AIRWA Inc. (YYAI), which posted an impressive +8.9% gain today, filed its 10-K on September 21st with a Health Score of 77.4—suggesting solid fundamentals beneath the hood. On the other end, Nutanix (NTNX) filed just ten days ago with a Health Score of only 37.0, a potential warning sign worth investigating. Campbell's (CPB) and Thor Industries (THO) both filed recently with more moderate health scores of 70.7 and 73.9 respectively.

Today's session exemplified a market in search of a new anchor. Commodity weakness, biotech optimism, and broad-based fund redemptions all played a role in the red close. For long-term investors, the day underscores why screening for financial health—not just price momentum—remains critical; a Money Checkup Health Score can help separate the genuine opportunities from the noise when markets get this fragmented.